MEDIVIS is a pharmaceutical company engaged in the Research & Development, Manufacture and Marketing of pharmaceutical products in the area of Ophthalmology.
MEDIVIS' goal is to become an international player in the ophthalmic market by building an innovative portfolio of products for ocular therapy. With a heritage of scientific and commercial expertise and on own research capabilities we are developing and marketing ophthalmic products that can help to enhance people's sight.
Our customers include hospitals, surgery centers, wholesalers, group purchasing organizations, retail pharmacies and other pharmaceutical companies.
MEDIVIS was founded in 1995 in Catania around its proprietary hyaluronic acid research platform, innovative drug-delivery systems and nanotechnology applied to ophthalmic formulations. A significant proportion of the Company's hyaluronic acid derived compounds and other high-tech products (association latanoprostâ€“dorzolamide, trans-epithelial riboflavin, association latanoprost-hyaluronic acid) have been developed through alliances with international pharmaceutical companies including TRB-Chemedica (Germany), Horus Pharma and TheÃ (France), Sirion and Alleanza (USA), as well as Italian and foreign Universities and Research Organizations (Santiago de Compostela-Spagna, La Sapienza-Roma, Catania University-Catania, Messina University-Messina, Consiglio Nazionale delle Ricerche).
Sito Web: http://www.medivis.it/